This site is intended for healthcare professionals

Keytruda filed at FDA to treat patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high.- Merck Inc.

Read time: 1 mins
Last updated:28th Jun 2021
Published:13th Apr 2020
Condition: Solid Tumours/Tumour Mutational Burden
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest